홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Acetic Acid → Brincidofovir

HRID 624683
인쇄

반응식

HRID 624683 반응식
C(O)(=[O:3])C.[CH3:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH2:14][CH2:15][CH2:16][CH2:17][CH2:18][CH2:19][CH2:20][O:21][CH2:22][CH2:23][CH2:24][O:25][P:26]1([O:32][CH2:31][C@H:30]([CH2:33][N:34]2[C:39](=[O:40])[N:38]=[C:37]([NH2:41])[CH:36]=[CH:35]2)[O:29][CH2:28]1)=[O:27]>[OH-].[Na+]>[CH3:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH2:14][CH2:15][CH2:16][CH2:17][CH2:18][CH2:19][CH2:20][O:21][CH2:22][CH2:23][CH2:24][O:25][P:26]([OH:32])([CH2:28][O:29][C@H:30]([CH2:31][OH:3])[CH2:33][N:34]1[C:39](=[O:40])[N:38]=[C:37]([NH2:41])[CH:36]=[CH:35]1)=[O:27]
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

4

반응물 2

HCID 176Acetic AcidHCID 483474Hexadecyloxypropyl-cyclic cidofovir

생성물 1

HCID 483477Brincidofovir

시약·촉매·용매 1

HCID 14798Sodium Hydroxide용매

실험 절차

As described in U.S. Pat. No. 6,716,825, in Step 1 of the scheme above, cidofovir was suspended in N,N-DMF and N,N′-dicyclohexyl-4-morpholine-carboxamide was added. The mixture was stirred overnight to dissolve the cidofovir. The clear solution was then charged to an addition funnel and slowly added (30 min) to a stirred, hot pyridine (60° C.) solution containing 1,3-dicyclohexyl carbodiimide. The resulting reaction mixture was stirred at 100° C. for 16 h, cooled to room temperature and the solvents were removed under reduced pressure. The reaction mixture was adsorbed on silica gel and the product was purified by flash column chromatography using gradient elution (CH2Cl2 and MeOH) followed by 5:5:1 CH2Cl2/MeOH/H2O. The fractions containing the product were combined and concentrated in vacuo. The product, the DCMC salt of cyclic cidofovir was isolated in a 44% yield. In step 2, a solution of cyclic cidofovir DCMC salt in dry N,N-DMF was charged with 1-bromo-3-hexadecyloxypropane and the mixture was stirred and heated at 80° C. for 6 h. The solution was concentrated in vacuo, the residue adsorbed on silica gel and purified by flash column chromatography using gradient elution (CH2Cl2 and ethanol). The product was eluted with 90:10 CH2Cl2/EtOH. The fractions containing pure product were concentrated in vacuo. Hexadecyloxypropyl-cyclic cidofovir was obtained in a 55% yield. In Step 3, hexadecyloxypropyl-cyclic cidofovir was dissolved in 0.5M NaOH and stirred at room temperature for 1.5 h. 50% aqueous acetic acid was then added dropwise to adjust the pH to 9. The precipitated hexadecyloxypropyl-cidofovir was isolated by filtration, rinsed with water, and dried. The product was crystallized from 3:1 p-dioxane/water to give hexadecyloxypropyl-cidofovir (HDP-CDV, i.e, CMX001).

출처 및 근거

ORD 기록
ord-c075d2e7362c4d4997fd879a9a4d996f
출처 데이터셋
uspto-grants-2016_04
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US09303051B2

반응 노트

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트